Mohammed (Mo) Ali is currently the global lead for digital development at Boehringer Ingelheim Pharmaceuticals. Prior to this role, he served as a Director within the R&D Operations and Innovations group at J&J Pharmaceuticals and also within the digital development group and Strategic Program Office at Novartis, responsible for several "E" initiatives within Digital Health. These programs aim to serve the needs of patients by creating a digital footprint and platform which would assist in the overall tracking, delivery, and enrichment of their experience.
Artificial intelligence holds the promise to revolutionize health care and directly impact the clinical trials process via expediting the recruitment of eligible clinical trial patients. The systems currently developed with the use of AI/ML enable higher patient enrollment rates and better trial assignment, contribute to reducing the cost of recruitment via additional/more efficient medical tests, and facilitate analysis and integration of operational data from historical cases. This session focuses on various applications of AI in clinical trial design and patient selection.